US nod to four Zydus Cadilla drugsMay 15th, 2008 - 4:02 pm ICT by admin
Mumbai, May 15 (IANS) The US Food and Drug Administration has granted approval to four drugs manufactured by the Gujarat-based pharmaceutical Zydus Cadilla. Announcing this Thursday, the company said authorities in the US had given the green signal to its fats-lowering agents and tentative approval to an anti-depressant, anti-hypertensive drug as well as a hormonal drug administered in the treatment of breast cancer.
The company said while anti-depressant Escitalopram Oxalate tablets had an annual sales turnover of $3 billion in 2007, the LDL cholesterol lowering drug Pravastain Sodium tablets, according to USFDA’s National Drug Code directory (NDC), has $1.9 billion American market.
The company quoted NDC to say that the hormonal therapy drug Anastrazole has an estimated market of $13 million and the anti-hypertensive Losartan Potassium and Hydrochlorthiazide had approximate sales touching $785 million last year.
Tags: anastrazole, anti depressant, breast cancer, cholesterol lowering drug, code directory, escitalopram, estimated market, food and drug administration, gujarat, hormonal therapy, ldl cholesterol, losartan, ndc, oxalate, sales turnover, tentative approval, treatment of breast cancer, us food and drug administration, usfda, zydus cadilla